Q3 EPS Estimates for Kura Oncology Boosted by HC Wainwright

Kura Oncology, Inc. (NASDAQ:KURA) – Analysts at HC Wainwright lifted their Q3 2026 earnings per share estimates for Kura Oncology in a research report issued to clients and investors on Thursday, August 13th. HC Wainwright analyst J. Pantginis now forecasts that the company will post earnings of ($0.85) per share for the quarter, up from their prior estimate of ($0.92). The consensus estimate for Kura Oncology’s current full-year earnings is ($3.30) per share. HC Wainwright also issued estimates for Kura Oncology’s FY2026 earnings at ($3.39) EPS, FY2027 earnings at ($2.45) EPS, FY2028 earnings at ($2.34) EPS and FY2029 earnings at ($2.16) EPS.

Several other analysts have also weighed in on the stock. Sanford C. Bernstein set a $24.00 target price on shares of Kura Oncology in a research report on Monday, June 15th. Cantor Fitzgerald reissued an “overweight” rating on shares of Kura Oncology in a research report on Thursday, June 4th. CLSA set a $24.00 price target on shares of Kura Oncology in a research note on Thursday, June 4th. Oppenheimer set a $24.00 price target on shares of Kura Oncology in a research note on Thursday, May 28th. Finally, Jefferies Financial Group set a $24.00 price objective on Kura Oncology in a report on Thursday, May 28th. Ten equities research analysts have rated the stock with a Buy rating, two have given a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat.com, Kura Oncology presently has an average rating of “Moderate Buy” and a consensus price target of $25.62.

Kura Oncology Trading Up 3.9%

Shares of KURA stock opened at $11.28 on Monday. Kura Oncology has a 52-week low of $6.95 and a 52-week high of $12.49. The stock has a market cap of $1.00 billion, a price-to-earnings ratio of -3.35 and a beta of 0.38. The company has a debt-to-equity ratio of 0.12, a quick ratio of 4.71 and a current ratio of 4.73. The firm has a fifty day moving average of $10.27 and a 200-day moving average of $9.36.

Kura Oncology (NASDAQ:KURA) last issued its earnings results on Wednesday, August 12th. The company reported ($0.77) EPS for the quarter, topping the consensus estimate of ($0.88) by $0.11. The firm had revenue of $20.87 million during the quarter, compared to analysts’ expectations of $20.16 million. Kura Oncology had a negative return on equity of 207.18% and a negative net margin of 384.30%.

Insiders Place Their Bets

In related news, CEO Troy Edward Wilson acquired 100,000 shares of the business’s stock in a transaction on Monday, August 17th. The stock was bought at an average cost of $11.12 per share, with a total value of $1,112,000.00. Following the completion of the acquisition, the chief executive officer owned 379,194 shares in the company, valued at $4,216,637.28. The trade was a 35.82% increase in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, insider Mollie Leoni sold 84,929 shares of the business’s stock in a transaction on Thursday, June 18th. The shares were sold at an average price of $9.82, for a total transaction of $834,002.78. Following the completion of the sale, the insider owned 182,345 shares in the company, valued at $1,790,627.90. This represents a 31.78% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. 7.60% of the stock is currently owned by company insiders.

Hedge Funds Weigh In On Kura Oncology

Several institutional investors have recently added to or reduced their stakes in the company. IFP Advisors Inc boosted its position in Kura Oncology by 115.3% in the fourth quarter. IFP Advisors Inc now owns 2,398 shares of the company’s stock valued at $25,000 after buying an additional 1,284 shares in the last quarter. Royal Bank of Canada increased its holdings in shares of Kura Oncology by 7.6% during the fourth quarter. Royal Bank of Canada now owns 19,577 shares of the company’s stock worth $203,000 after buying an additional 1,375 shares in the last quarter. Allworth Financial LP increased its holdings in shares of Kura Oncology by 59.9% during the fourth quarter. Allworth Financial LP now owns 4,146 shares of the company’s stock worth $43,000 after buying an additional 1,553 shares in the last quarter. Focus Partners Advisor Solutions LLC raised its stake in shares of Kura Oncology by 7.9% in the fourth quarter. Focus Partners Advisor Solutions LLC now owns 22,889 shares of the company’s stock valued at $238,000 after acquiring an additional 1,682 shares during the last quarter. Finally, ProShare Advisors LLC raised its stake in shares of Kura Oncology by 10.0% in the fourth quarter. ProShare Advisors LLC now owns 18,572 shares of the company’s stock valued at $193,000 after acquiring an additional 1,692 shares during the last quarter.

About Kura Oncology

Kura Oncology, Inc (NASDAQ: KURA) is a clinical-stage biopharmaceutical company focused on the discovery and development of targeted oncology therapies. Headquartered in La Jolla, California, the company leverages expertise in molecular biology and precision medicine to identify key drivers of cancer growth and design small-molecule inhibitors that block those pathways. Kura’s research platform integrates genomic insights with medicinal chemistry to advance candidates against well-validated targets in solid tumors and hematologic malignancies.

The company’s lead clinical candidate, tipifarnib, is a farnesyltransferase inhibitor being evaluated for the treatment of HRAS-mutant head and neck squamous cell carcinoma and various non-small cell lung cancers.